Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain, Aug. 29-Sept. 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF).
“Cardiovascular disease remains the leading cause of death worldwide, and Merck is committed to addressing this urgent public health challenge through research and innovative science,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “At this year’s congress, the data we are presenting reflect our continued commitment to advancing cardiovascular research with the goal of improving outcomes for patients at risk around the world.”
Merck will share two oral presentations focused on the treatment patterns and burdens for patients living with ASCVD. The first presentation evaluates the clinical and economic burden on patients with and without myocardial infarction using a nationwide 10-year registry; the second explores temporal trends in lipid-lowering therapy utilization in a large-scale patient population with ASCVD. These data demonstrate Merck's commitment to advancing research focused on patients living with ASCVD and highlight opportunities for improved disease management in a real-world setting.
Key details on clinical trial research for WINREVAIR (sotatercept-csrk) in PH will be shared. The rationale and design of the Phase 2 study CADENCE in adults with combined post- and precapillary pulmonary hypertension (Cpc-PH) associated with heart failure with preserved ejection fraction (HFpEF) will be featured. Additionally, results from the ZENITH trial describing the effect of WINREVAIR on hemodynamics in high-risk pulmonary arterial hypertension (PAH) will also be presented.
Merck will also share two hot line oral presentations and two supplementary poster presentations evaluating VERQUVO (vericiguat) in adult patients with HFrEF from the VICTOR trial and a pooled-analysis of the VICTOR and VICTORIA trials, along with real-world analyses.
For more information, visit www.msd.com.
November 17, 2025 
